Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El.En. SpAELEAF 64 Cash-to-Debt is 18.01 as of Jun. 2026, which is 456% above its 10-year median of 3.24. GuruFocus rates ELEAF with a GF Score™ of 64/100 and a GF Value™ of $10.55 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, El.En. SpA ranks better than 79.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. El.En. SpA's cash to debt ratio for the quarter that ended in Jun. 2026 was 18.01.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, El.En. SpAcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for El.En. SpA's Cash-to-Debt or its related term are showing as below:
ELEAF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.24 Med: 3.24 Max: No Debt
Current: 18.01
During the past 13 years, El.En. SpA's highest Cash to Debt Ratio was No Debt. The lowest was 1.24. And the median was 3.24.
ELEAF's Cash-to-Debt is ranked better than 79.57% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ELEAF: 18.01
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
El.En. SpA Cash-to-Debt Related Terms
El.En. SpA Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for El.En. SpA's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, El.En. SpA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where El.En. SpA's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El.En. SpA (ELEAF) has a Cash-to-Debt of 18.01 as of Jun. 2026. This is 456% above median its historical median of 3.24. Over the past decade, El.En. SpA's Cash-to-Debt has ranged from 1.24 to 10,000.00. According to the industry distribution chart, El.En. SpA ranks #172 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is El.En. SpA's Cash-to-Debt too high?
El.En. SpA's current Cash-to-Debt of 18.01 is 456% above median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. El.En. SpA's value of 18.01 is 1001.5% above this industry median. Based on the distribution chart, El.En. SpA ranks #172 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, El.En. SpA has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #172 out of 842 companies for Cash-to-Debt. This places El.En. SpA in the top 20% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.64. El.En. SpA's value of 18.01 is 1001.5% above this benchmark. Historically, El.En. SpA's own Cash-to-Debt has ranged from 1.24 to 10,000.00 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 1.64, El.En. SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current Cash-to-Debt of 18.01 is 1001.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current Cash-to-Debt is 18.01, which is 456% above median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.55, compared to a current price of $17.50 — trading 65.9% above its estimated fair value. The current Cash-to-Debt is 18.01, which is 456% above median its 10-year median of 3.24 and 1001.5% above the Medical Devices & Instruments industry median of 1.64. El.En. SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current Cash-to-Debt is 18.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (ELEAF) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of $17.50 is trading 65.9% above its estimated GF Value™ of $10.55.
GuruFocus considers El.En. SpA to be Significantly Overvalued.
Key valuation signals for ELEAF:
Cash-to-Debt: 18.01 (456% above median its 10-year median of 3.24)
GF Value™: $10.55 vs. price of $17.50 (65.9% above fair value)
Industry Position: 1001.5% above the Medical Devices & Instruments median (#172 of 842)
No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
64GF Score
Get the complete analysis for ELEAF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELEAF has been successfully added to your 
